Improving the risk-benefit relationship and informed consent for patients treated with hydroxychloroquine

Transactions of the American Ophthalmological Society

Volumn 105, Issue , 2007, Pages 191-194

  Flach, Allan J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE;

ADULT; ARTICLE; DRUG INDUCED DISEASE; EYE EXAMINATION; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RETINOPATHY; RISK BENEFIT ANALYSIS; RISK FACTOR; SCREENING; STATISTICAL SIGNIFICANCE; VETERAN;

ARTHRITIS, RHEUMATOID; CHLOROQUINE; HUMANS; HYDROXYCHLOROQUINE; INFLAMMATION; INFORMED CONSENT; LUPUS ERYTHEMATOSUS, SYSTEMIC; RETINAL DISEASES; RISK ASSESSMENT; RISK FACTORS; SKIN DISEASES;

EID: 47749143195     PISSN: None     EISSN: 15456110     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Hobbs HE, Sorby A, Freedman A. Retinopathy following chloroquine therapy. Lancet 1959;2:478-480.
2. Shearer RV, Dubois EL. Ocular changes induced by long-term hydroxychloroquine (Plaquenil) therapy. Am J Ophthalmol 1967;64:245-252.
3. Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2002;109:1377-1382.
4. Gupta G, Greenberg PB, Tsiaras WG. The prevalence of high-risk factors and adherence to screening guidelines for hydroxychloroquine retinopathy in a cohort of US veterans. Scientific poster 461. Presented at: American Academy of Ophthalmology 2005 Annual Meeting; Oct 17-18, 2005; Chicago.
5. Finbloom DS, Silver K, Newsome DA, Gunkel R. Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity. J Rheumatol 1985;12:692-694.
6. Johnson MW, Vine AK. Hydroxychloroquine therapy in massive total doses without retinal toxicity. Am J Ophthalmol 1987;104:139-144.
7. Ehrenfeld M, Nesher R, Merin S. Delayed-onset chloroquine retinopathy. Br J Ophthalmol 1986;70:281-283.
8. Burns RP. Delayed onset of chloroquine retinopathy. N Engl J Med 1966;275:693-696.
9. Martin LJ, Bergen RL, Dobrow HR. Delayed onset chloroquine retinopathy. Ann Ophthalmol 1978;10:723-726.
10. Brinkley JR, Dubois EL, Ryan SJ. Long-term course of chloroquine retinopathy after cessation of medication. Am J Ophthalmol 1979;88:1-11.
11. Easterbrook M. Long-term course of antimalarial maculopathy after cessation of treatment. Can J Ophthalmol 1992;27:237-239.
12. Coyle JT, Easterbrook M. Hydroxychloroquine retinopathy. Ophthalmology 2001;108:2158-2159.
13. Elder M, Rahman MA, McLay J. Early paracentral visual field loss in patients taking hydroxychloroquine. Arch Ophthalmol 2006;124:1729-1733.
14. Vu BL, Easterbrook M, Hovis JK. Detection of color vision defects in chloroquine retinopathy. Ophthalmology 1999;106:1799-1804.
15. Kellner U, Renner AB, Tillack H. Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/ hydroxychloroquine. Invest Ophthalmol Vis Sci 2006;47:3531-3538.
16. Lee AG. Hydroxychloroquine screening. Br J Ophthalmol 2005;89:521-522.